Weekly diabetes jab shown to reduce blood-sugar levels and body weight

A new triple-action weekly jab for type 2 diabetes, retatrutide, showed significant reductions in blood sugar and body weight in phase 3 trials. Patients receiving retatrutide lost over four times more weight and experienced more than twice the drop in HbA1c compared to placebo. The drug mimics three gut hormones (GLP-1, GIP, and glucagon) and differs from existing diabetes medications by engaging the glucagon receptor to increase energy expenditure.